469 Incidence of selected adverse events (AEs) in phase III studies of bevacizumab (BV) in combination with chemotherapy for the treatment of HER2-negative metastatic breast cancer (mBC)
| Autor: | Miles, D.W., Dieras, V., Glaspy, J., Brufsky, A., Koralewski, P., Phan, S.C., Robert, N.J. |
|---|---|
| Zdroj: | In EJC Supplements 2010 8(3):196-196 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect